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Case Report
Primary hyperparathyrodism in pregnancy and review of literature
Tahira Naru,1 Rozilla Sadia Khan,2 Mohammed Ataullah Khan3
Department of Obstetrics and Gynaecology,1,2 Department of Medicine,3 Aga Khan University Hospital, Karachi, Pakistan.
Abstract
Primary hyperparathyroidism (PHPT) is rare
condition during pregnancy; however, it can carry significant
risks to both mother and foetus during and after the
pregnancy. The definitive treatment is parathyroidectomy
undertaken preferably in the second or early third trimester. A
case of asymptomatic PHPT diagnosed and treated by
parathyroidectomy in the third trimester is described.
Keywords: Hyperparathyroidism, Parathyroid adenoma,
hypercalcaemia, pregnancy.
Introduction
PHPT is an uncommon condition, usually diagnosed
in people in their fifth or sixth decade of life. Its prevalence
in the general population is 0.15%. Although the exact
incidence during pregnancy is not known, the incidence of
PHPT in women of child bearing age is estimated to be 8
cases per 100,000 per year.1 Physiological changes associated
with pregnancy make this condition difficult to diagnose, and
80% of affected pregnant women are found to be
asymptomatic. The pregnant female is at a risk of significant
pregnancy problems and complications ranging from an
uncomplicated delivery to miscarriages, stillbirth or even
neonatal death.1,2 It is therefore important for the obstetrician,
surgeon, paediatrician and endocrinologist to be aware of this
condition, and its potential complications to define a clear
approach for its management.
We present a case of asymptomatic primary
hyperparathyroidism treated by parathyroidectomy in the
third trimester, in a mother after the development of tetany in
a new born infant.
Case Report
A 23-year-old woman, gravida 2, Para 1, was booked
at 19 weeks gestation. Her previous pregnancy was
uneventful, but at 3 months of age her daughter had had
seizures and was found to have low calcium and vitamin D
levels with normal Parathyroid hormone (PTH) levels. She
was given calcium and vitamin D therapy. The mother was
also evaluated and found to have calcium levels of 10.6mg/dl
(normal range 8.6-10.5) borderline high and very low
Vitamin D levels <1.1ng/ml (Normal range => 30ng/ml).
PTH was not done. She was given intramuscular injection of
600,000 IU vitamin D once a month for six months. After
treatment her vitamin D level was 23.6 ng/ml.
On the basis of the previous history of seizures in the
infant, she was investigated in the index pregnancy when
vitamin D level was normal (28.92 ng/ml) and calcium levels
were raised (12.7 mg/dl). She was referred to the
endocrinologist. 
Further investigation revealed raised PTH 224 pg/mg
(normal 18-67) with decreased serum phosphorus and
magnesium (1.6 mg/dl) with normal urinary calcium (238
mg/24hour) and renal functions. An Ultrasound scan of the
thyroid and parathyroid revealed normal texture of both lobes
of thyroid and a hypoechoic mass lesion measuring 8.4 X 6.4
mm seen on the posterior-inferior to lower pole of left thyroid
lobe. Colour Doppler showed normal flow. The diagnosis of
primary hyperparathyroidism was made on the basis of
biochemical and radiological investigations at 22 weeks of
gestation.
Patient consented for Parathyroidectomy after 5
weeks due to fear of complications. A left inferior
parathyroidectomy was performed at 27 weeks gestation with
cyclogest given postoperatively as a tocolytic drug. Transient
hypocalcaemia was observed in the postoperative period and
calcium carbonate 2gm daily was started. Calcidol 0.25 mcg
was also given orally to prevent hypocalcaemia.
Histopathology confirmed a benign adenoma weighing 0.3
gm. The foetus was monitored by serial growth scans and
remained normal. Patient opted for an elective caesarean
section at 38 gestational weeks and delivered a healthy baby
boy weighing 3 kilogram with good Apgar scores. Her
postoperative period was uneventful. She is currently
maintaining a calcium level of 9.0 dl/ml on one gram calcium
intake per day. The baby was also monitored with calcium
level and maintained his calcium level without development
of any seizure yet at the age of ten months.
Discussion
Primary hyperparathyroidism in pregnancy needs to
be recognized and treated due to the risks it confers to both
mother and foetus. In the mother, the symptoms of
hypercalcaemia secondary to hyperparathyroidism are
similar to those in the non-pregnant patient.3 Maternal and
foetal complication rates have been quoted to be as high as
67% and 80% respectively.4,5 Nephrolithiasis is the most
common symptomatic presentation with an increased
incidence of 24-36% during pregnancy.6
Approximately 40% of patients with PHPT are
hypercalciuric, and most of the remaining patients have
normal values.7 The calcium excreted in a 24-h urine
collection varies with age, sex, and race, and one 24-h
collection does not capture the large variability in the
measurement, therefore most studies on PHPT use serum
calcium and PTH for assessment.8
Other complications include bone disease (osteitis
fibrosa cystica), pancreatitis and hyperemesis gravidarum.
Potentially, the most serious maternal complication is
hypercalcaemic crisis, which classically presents with
nausea, vomiting, weakness, dehydration and altered mental
state changes. There can also be a rapid progression to
uraemia, coma and death.2,4 Other manifestations of PPHT
include spontaneous miscarriage, intrauterine growth
retardation, low birth weight, premature delivery and
intrauterine foetal death. In the postpartum period, maternal
hypercalcaemia can worsen due to the removal of the foetal
demand for calcium. Untreated hyperparathyroidism has 80%
foetal complication rate.6 The incidence of a neonatal
complication has been reported as high as 53% of which 27 -
31% is neonatal death.3,5
Symptomatic PPHT is rarely detected in pregnancy
due to the physiological changes that mask the symptoms,
this includes maternal blood volume expansion,
hypoalbuminaemia, increased foetal calcium requirements,
and increased calcium clearance.
Calcium metabolism in pregnancy is a dynamic
process. Maternal serum calcium falls by about 10% in
pregnancy; however as the serum albumin falls by 20%, the
ionized calcium remains unchanged. Foetal 1, 25-
dihydroxyvitamin D, synthesized in foetal kidney and
placenta, acts as the major stimulus and regulator of calcium
transfer across the placenta.
It increases maternal gastrointestinal absorption of
calcium by 150mg -400mg daily, additionally maternal
urinary excretion is also increased from 90 to 300 mg daily.
Major foetal calcium demands of approximately 25-30g, are
required in the 3rd trimester for skeletal tissue mineralization.
This requires an active transport of calcium across the
placenta and the foetal serum calcium remains higher than
maternal blood. 
Primary hyperparathyroidism results in high
concentrations of foetal serum calcium that acts to suppress
the parathyroid glands. Foetal calcitonin concentrations are
high to encourage bone mineralization. At birth however, the
neonate is suddenly deprived of this source of calcium. It is
incapable of mobilizing calcium from bone owing to the low
concentrations of parathyroid hormone and high
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concentrations of calcitonin. Acute neonatal hypocalcaemia
results in tetany and convulsions, usually at 5 to 14 days of
age. If the infant is breast fed, tetany can be delayed by one
month or more.2,9
Diagnosis of primary hyperparathyroidism should be
confirmed by elevated serum calcium and PTH levels.
Preoperative imaging by ultrasound of the parathyroid glands
is recommended. Parathyroid ultrasound has a sensitivity of
69% and specificity of 94% and is safe in pregnancy. The
gold standard is Technetium-99m sestamibi and ultrasound,
with a combined sensitivity of 94.5%.10 However,
Technetium-99m sestamibi is contraindicated in pregnancy
and mostly an ultrasound will suffice. 
Other causes of hypercalcaemia like excessive
ingestion of calcium and vitamin D, thiazide diuretics,
lithium therapy, sarcoidosis and haemoconcentration must be
ruled out. Studies suggest that the foetal mortality rate can be
reduced by a factor of four if operative cure is achieved.5,6
Management:
Treatment of hyperparathyroidism during pregnancy
should be individualized, based on the severity of disease,
symptoms, and gestational age of the foetus. A significant
decline in maternal and peri natal complications may be
achieved with a high index of suspicion, appropriate
diagnosis, and timely management of mothers. In certain
situations intervention may be required, but excision of
parathyroid adenoma remains the only definitive treatment.
In most reported cases, the adenoma accounts for 90%
of primary hyperparathyroidism, carcinoma for 2% and
hyperplasia (8-9%) for the remaining number of cases.3
Role of medical therapy in pregnancy: 
Medical therapy in pregnancy for symptomatic
primary hyperparathyroidism has been discouraged, due to
safety issues of drug therapy, and the suboptimal control of
serum calcium which leads to a high foetal loss rate.6
However in symptom-free patients or those with no
radiologically identifiable parathyroid adenoma or those with
mild hypercalcaemia diagnosed in 3rd trimester, may be
managed medically, postponing operation until after delivery.
If conservative management is considered intensive maternal
and foetal surveillance should be initiated.
Medical therapy primarily involves stabilizing the
patient with hydration, limiting calcium intake, correcting
electrolyte imbalance, administration of magnesium sulfate,
oral phosphate and calciuretic diuretics.2,3
Role of surgery: 
Symptomatic and poorly controlled hypercalcaemic
patients should be offered surgical resection which can be
carried out in the second or early third trimester. 
Earlier reports have suggested low complication rates,
most common being laryngeal nerve injury or
hypoparathyroidism, with a quoted mortality rate of 0.1%.6
However a recent review of surgically managed patients who
underwent parathyroidectomy even in the third trimester,
found it to be effective and safe with reduced maternal and
foetal risk for complications. Post operative hypocalcaemia
can be easily managed with calcium and vitamin D
supplementation.6,11
Conclusion 
Primary hyperparathyroidism during pregnancy
though rare, is associated with high maternal, foetal and
neonatal mortality. Increased awareness, earlier detection,
and better management are the key to decreasing its
complications. A surgical option should be considered in
view of a poor control of the hypercalcaemic state in
pregnancy by medical or conservative management.
Hyperparathyroidism during pregnancy may be safely treated
with parathyroidectomy when performed during the second
trimester or early third trimester.
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